Targeting the Complement Cascade for Treatment of Dry Age-Related Macular Degeneration

Patel, Prem N.; Patel, Pujan; Land, Matthew R.; Bakerkhatib-Taha, Ibrahim; Ahmed, Harris; Sheth, Veeral

doi:10.3390/biomedicines10081884

Cited by 11 publications

(9 citation statements)

References 97 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Targeting the complement cascade appears to be the more promising therapeutic approach, as has been recently comprehensively reviewed by Patel and colleagues [ 143 ] but no drug has been marketed yet.…”

Section: Resultsmentioning

confidence: 99%

Recent Advances in Proteomics-Based Approaches to Studying Age-Related Macular Degeneration: A Systematic Review

García-Quintanilla

Rodríguez-Martínez²,

Bandín-Vilar

et al. 2022

IJMS

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is a common ocular disease characterized by degeneration of the central area of the retina in the elderly population. Progression and response to treatment are influenced by genetic and non-genetic factors. Proteomics is a powerful tool to study, at the molecular level, the mechanisms underlying the progression of the disease, to identify new therapeutic targets and to establish biomarkers to monitor progression and treatment effectiveness. In this work, we systematically review the use of proteomics-based approaches for the study of the molecular mechanisms underlying the development of AMD, as well as the progression of the disease and on-treatment patient monitoring. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) reporting guidelines were followed. Proteomic approaches have identified key players in the onset of the disease, such as complement components and proteins involved in lipid metabolism and oxidative stress, but also in the progression to advanced stages, including factors related to extracellular matrix integrity and angiogenesis. Although anti-vascular endothelial growth factor (anti-VEGF)-based therapy has been crucial in the treatment of neovascular AMD, it is necessary to deepen our understanding of the underlying disease mechanisms to move forward to next-generation therapies for later-stage forms of this multifactorial disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Recent Advances in Proteomics-Based Approaches to Studying Age-Related Macular Degeneration: A Systematic Review

García-Quintanilla

Rodríguez-Martínez²,

Bandín-Vilar

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Targeting the complement cascade appears to be the more promising therapeutical approach, as has been recently comprehensively reviewed by Patel and colleagues [143] but no drug has been marketed yet.…”

Section: Therapeutical Challenges and Future Directionsmentioning

confidence: 99%

Recent Advances in Proteomic-based Approaches to Study Age-related Macular Degeneration: A Systematic Review

García-Quintanilla¹,

Rodríguez-Martínez²,

Bandín-Vilar³

et al. 2022

Preprint

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is a common ocular disease characterized by the de-generation of the central area of the retina in elderly population. Progression and response to treatment is influenced by genetic and non-genetic factors. Proteomics is a powerful tool to study, at the molecular level, the mechanisms underlaying the progression of the diseases, to identify new therapeutical targets and to establish biomarkers to monitor progression and treatment ef-fectiveness. In this work we pursue to systematically review the use of proteomic-based ap-proaches for the study of the molecular mechanisms underlying the development of AMD, as well as the progression of the disease and the on-treatment patient monitoring. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines were followed. Proteomic approaches have identified key players on the onset of the disease, such as proteins involved in lipid metabolism and oxidative stress, but also in the progression to advanced stages, including factors related to extracellular matrix integrity and angiogenesis. Although an-ti-vascular endothelial growth factor (anti-VEGF)-based therapy has been crucial in the treatment of neovascular AMD it is necessary to get deeper into the underlying disease mechanisms to move forward to next-generation therapies of the later-stage forms of this multifactorial disease.

show abstract

“…Also, multiple genes related to complement cascade ( CHF , C3 ) and inflammatory parameters ( IL8 ) have been suggested to be related to AMD development [ 12 ]. Although various of these proinflammatory and proangiogenic mediators have been reported in the literature to be involved in nAMD, vascular endothelial growth factor (VEGF) keeps being the main target of nAMD therapy [ 13 , 14 ], while the treatment of geographic atrophy (GA) focuses on the complement cascade [ 15 ]. In any case, both treatments seek to stop the progression of the disease.…”

Section: Introductionmentioning

confidence: 99%

The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration

García-Quintanilla,

Almuiña-Varela,

Rodríguez-Cid

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Anti-vascular endothelial growth factor drugs keep being the main therapy for neovascular age-related macular degeneration (AMD). Possible predictive parameters (demographic, biochemical and/or inflammatory) could anticipate short-term treatment response with ranibizumab. 46 treatment-naive patients were included in a prospective observational study. They underwent three monthly injections of intravitreal ranibizumab for neovascular AMD and the clinical examination was made at baseline and one month after the third injection. Demographic characteristics, co-morbidities and concomitant treatments were recorded at the baseline visit. Biochemical parameters, complete blood count and inflammation biomarkers were also measured at these times. Uric Acid was found to be statistically significant with a one-point difference between good and poor responders in both basal and treated patients, but only in basal parameters was statistical significance reached (p = 0.007 vs. p = 0.071 in treated patients). Cholesterol and inflammatory parameters such as white blood cell count and neutrophils were significantly reduced over time when treated with intravitreal ranibizumab. On the other hand, women seemed to have a worse prognosis for short-term response to intravitreal ranibizumab treatment. Uric acid may help identify possible non-responders before initial treatment with ranibizumab, and cholesterol and white blood cells could be good candidates to monitor short-term response to ranibizumab treatment.

show abstract

Targeting the Complement Cascade for Treatment of Dry Age-Related Macular Degeneration

Cited by 11 publications

References 97 publications

Recent Advances in Proteomics-Based Approaches to Studying Age-Related Macular Degeneration: A Systematic Review

Recent Advances in Proteomics-Based Approaches to Studying Age-Related Macular Degeneration: A Systematic Review

Recent Advances in Proteomic-based Approaches to Study Age-related Macular Degeneration: A Systematic Review

The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration

Contact Info

Product

Resources

About